BMJ Group Logo

GP-led talking therapy eases PTSD symptoms after critical illness

Effects modest but intervention may bridge long waiting times between ICU discharge and access to specialist mental health services, say researchers A brief spell of talking therapy with a general practitioner reduces symptoms of post-traumatic stress disorder (PTSD) for survivors of critical illness, finds a trial from Germany published by The ...

2025-05-08T08:00:17+01:008 May 2025|Press release, The BMJ|

Yearly 18% rise in ADHD prescriptions in England since COVID-19 pandemic

Figures reflect growing public and professional awareness and potential impact of COVID-19 But wide regional variations point to inequalities in access to care, say researchers  Prescriptions for attention deficit hyperactivity disorder (ADHD) in England have risen 18%  year on year since the pandemic. This is higher than previously reported, and ...

2025-03-12T09:58:26+00:0012 March 2025|BMJ Mental Health, Press release|

Men often struggle with transition to fatherhood amid lack of targeted information and support

Greater focus needed on their unique experiences of perinatal period, say researchers Men often struggle with the transition to fatherhood amid a lack of information and emotional support targeted to their needs, suggests a review of the available qualitative evidence, published in the open access journal BMJ Open. Greater focus is ...

2024-11-13T10:52:31+00:0013 November 2024|BMJ Open, Press release|

Suicide risk highest on Mondays and New Year’s Day

But risk patterns vary on weekends and Christmas by country and region Suicide risk is highest on Mondays and increased on New Year’s Day, whereas suicide risk on weekends and Christmas varies by country and region, finds an analysis of data from 26 countries published by The BMJ today. The researchers say ...

2024-10-24T11:17:49+01:0024 October 2024|Press release, The BMJ|

Certain diabetes drugs might prevent dementia

But randomised controlled trials are needed to confirm these findings Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes might prevent dementia, providing greater benefits with longer treatment, suggests a large study from Korea published by The BMJ today. As this study was observational, the researchers note that the effect size ...

2024-08-29T07:46:52+01:0029 August 2024|Press release, The BMJ|

New study provides further support for psilocybin’s potential to treat depressive symptoms

High dose psilocybin was the only psychedelic treatment to reduce depressive symptoms by more than placebo in antidepressant trials High doses of psilocybin - the active ingredient in magic mushrooms - appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor (SSRI) drug escitalopram, suggests ...

2024-08-22T10:48:26+01:0022 August 2024|Press release, The BMJ|
Go to Top